Acceptance Limits for the New ICH USP 29 Content-Uniformity Test - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Acceptance Limits for the New ICH USP 29 Content-Uniformity Test
Revisions to the United States Pharmacopeia's (USP) uniformity test require manufacturers to establish new acceptance limits. The authors present their method for calculating acceptance limits consistent with USP's revised content-uniformity test requirements.


Pharmaceutical Technology


References

1. United States Pharmacopeia, "‹905› Uniformity of Dosage Units," Pharmacopeial Forum 32 (6), 1653–1659, 2006.

2. Statistics Working Group of PhRMA, "Content Uniformity: Evaluation of the USP Pharmacopeial Preview," Pharmacopeial Forum 24 (5), 7029–7044, 1998.

3. Statistics Working Group of PhRMA, "Content Uniformity: Alternative to the USP Pharmacopeial Preview," Pharmacopeial Forum 25 (2), 7939–7948, 1999.

4. Statistics Working Group of PhRMA, "Recommendations for a Globally Harmonized Uniformity of Dosage Units Test," Pharmacopeial Forum , 25 (4), 8609–8624, 1999.

5. J.S. Bergum, "Constructing Acceptance Limits for Multiple Stage Tests," Drug Dev. Ind. Pharm. 16 (14), 2153–2166, 1990.

6. J.S. Bergum and M.L. Utter, "Process Validation," in Encyclopedia of Biopharmaceutical Statistics, S.C. Chow, Ed., (Marcel Dekker, New York, 2000), pp. 422–439.

7. J.S. Bergum and M.L. Utter, "Statistical Methods for Uniformity and Dissolution Testing" in Pharmaceutical Process Validation, Robert A. Nash and Alfred H. Watchter, Eds., (Marcel Dekker, New York, 2003), pp. 667–697.

8. J. S. Bergum's SAS Programs, Content Uniformity and Dissolution Acceptance Limits (CUDAL), version: 1.0, validation completed 02/11/02.

9. J.B. Berman et al., "Blend Uniformity Analysis: Validation and in-process testing," Technical Report No. 25, PDA J. Pharm. Sci. Technol. (suppl.) 51, 1997.

10. B.W. Lindgren, "Normal Populations" in Statistical Theory, C. B. Allendoerfer, (Macmillan, New York,1968), 390–391.

11. F.A. Graybill and C.M. Wang, "Confidence Intervals on Nonnegative Linear Combination of Variances," J. Am. Stat. Assoc. 75 (372), 869–873, 1980.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here